Stockscreener 앱 받기
3.17
0.00%
0.00
시간 외 거래:
3.13
-0.04
-1.26%
전일 마감가:
$3.17
열려 있는:
$3.215
하루 거래량:
13.47M
Relative Volume:
0.68
시가총액:
$1.67B
수익:
$74.68M
순이익/손실:
$-644.76M
주가수익비율:
-2.1377
EPS:
-1.4829
순현금흐름:
$-380.44M
1주 성능:
-4.52%
1개월 성능:
-15.92%
6개월 성능:
-31.53%
1년 성능:
-51.45%
1일 변동 폭
$3.11
$3.2853
1주일 범위
$3.08
$3.45
52주 변동 폭
$2.98
$7.18
리커젼 파마 Stock (RXRX) Company Profile
명칭
Recursion Pharmaceuticals Inc
전화
(385) 269-0203
주소
41S RIO GRANDE STREET, SALT LAKE CITY
Compare RXRX vs VRTX, REGN, ALNY, ARGX, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
3.17 | 1.67B | 74.68M | -644.76M | -380.44M | -1.4829 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
리커젼 파마 Stock (RXRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-17 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2025-07-03 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-05-22 | 개시 | Morgan Stanley | Equal-Weight |
| 2023-03-16 | 개시 | Needham | Buy |
| 2022-09-16 | 개시 | KeyBanc Capital Markets | Overweight |
| 2022-04-18 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-03-04 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-09-21 | 개시 | Berenberg | Buy |
| 2021-05-11 | 개시 | BofA Securities | Buy |
| 2021-05-11 | 개시 | Goldman | Neutral |
| 2021-05-11 | 개시 | JP Morgan | Neutral |
| 2021-05-11 | 개시 | KeyBanc Capital Markets | Overweight |
| 2021-05-11 | 개시 | SVB Leerink | Outperform |
모두보기
리커젼 파마 주식(RXRX)의 최신 뉴스
Recursion Pharmaceuticals Names New Chief Medical Officer - TipRanks
Recursion appoints Vicki Goodman as Chief Medical Officer; David Mauro to transition to advisor - TradingView
EXEL: Former Executive Joins Recursion Pharmaceuticals as New CM - GuruFocus
Recursion Announces Vicki Goodman, M.D., as Incoming Chief Medical Officer - marketscreener.com
Assessing Recursion Pharmaceuticals (RXRX) Valuation After Prolonged Share Price Weakness - Sahm
Recursion Pharmaceuticals Stock (RXRX) Opinions on Roche's AI Drug Development Commitment - Quiver Quantitative
Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Prediction: The "Trough of Disillusionment" Will Create the Best Buying Opportunity for Artificial Intelligence (AI) Stocks in 2026 - The Motley Fool
Recursion Pharmaceuticals Details AI-Driven Drug Pipeline, Sanofi/Roche Milestones, Runway to 2028 - MarketBeat
Recursion’s Khan: AI will be judged by the medicines it makes - BioCentury
Recursion Pharmaceuticals (RXRX) Advances While Market Declines: Some Information for Investors - Yahoo Finance
What makes Recursion Pharmaceuticals (RXRX) so attractive - MSN
Ben Taylor Sells 7,956 Shares of Recursion Pharmaceuticals (NASDAQ:RXRX) Stock - MarketBeat
Recursion Pharma CFO Taylor sells $26970 in shares - Investing.com
CFO of Recursion Pharmaceuticals (RXRX) sells 7,956 shares under 10b5-1 plan - Stock Titan
Recursion Pharmaceuticals sets post-hype agenda at LeerinkPartners healthcare event - Traders Union
BofA lowers PT on Recursion Pharmaceuticals (RXRX), keeps a hold rating - MSN
Jim Cramer on Recursion Pharmaceuticals: “It’s a let down, big let down” - MSN
Why Recursion Pharmaceuticals, Inc. (RXRX)'s upside case hasn't fully convinced yet - MSN
RXRX SEC FilingsRecursion Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Is Recursion Pharmaceuticals, Inc. (RXRX) the best fundamentally strong penny stock to buy? - MSN
Costco, AMD, Recursion Pharmaceuticals, Cipher Mining And Snowflake: Why These 5 Stocks Are On Investors' Radars Today - AOL.com
Measuring the AI Bubble - Pharmaceutical Executive
Jim Cramer on Recursion Pharmaceuticals: “It’s a Let Down, Big Let Down” - Insider Monkey
A Look At Recursion Pharmaceuticals (RXRX) Valuation After Q4 Beat And AI Clinical Progress - Sahm
PARG inhibitors disclosed in Recursion Pharmaceuticals patent - BioWorld MedTech
Recursion Pharmaceuticals and Applied Digital shares fall after Nvidia exits stakes - MSN
Needham Retains Buy Rating on Recursion Pharmaceuticals, Maintains PT at $8 - MSN
Recursion Pharmaceuticals (NASDAQ:RXRX) CEO Sells $94,798.30 in Stock - MarketBeat
Recursion (NASDAQ: RXRX) director converts 20K Class B, gifts 20K A - Stock Titan
Jim Cramer on Recursion: “It is so low that it comes in under the category of speculative” - MSN
Recursion Pharmaceuticals (RXRX) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Yahoo Finance
Is Recursion Pharmaceuticals (RXRX) Pricing Reflect Recent 1‑Year Share Slump Accurately - Yahoo Finance
How Recursion’s AI Proof of Concept and Equity Raise Will Impact Recursion Pharmaceuticals (RXRX) Investors - Yahoo Finance
A Look At Recursion Pharmaceuticals (RXRX) Valuation After AI Milestone And Improved Quarterly Results - Yahoo Finance
Recursion’s First AI Clinical Proof Links Pipeline Progress With Valuation Gap - Yahoo Finance
What Makes Recursion Pharmaceuticals (RXRX) So Attractive - Finviz
Recursion rises on new data for asset for polyps - MSN
Can This AI Stock Bounce Back in 2026? - Yahoo Finance
Day Trade: Why retail investors pile into Recursion Pharmaceuticals Inc. stockTrade Analysis Summary & Community Supported Trade Ideas - Naître et grandir
symbol__ Stock Quote Price and Forecast - CNN
10 Low Risk Penny Stocks to Buy Now - Insider Monkey
Recursion Pharmaceuticals’ Earnings Call Highlights AI Momentum - TipRanks
Recursion Pharmaceuticals Acquires Full Rights to REV102, Potential Oral Therapy for Rare Bone Disorder Hypophosphatasia - MSN
BoFA Lowers PT on Recursion Pharmaceuticals (RXRX), Keeps a Hold Rating - Insider Monkey
Assessing Recursion Pharmaceuticals (RXRX) Valuation After Earnings Jump And New Equity Offering Plans - Sahm
ARK Investment Management LLC Purchases 556,868 Shares of Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
Recursion Pharmaceuticals, Inc. $RXRX Stake Cut by Amova Asset Management Americas Inc. - MarketBeat
Top Recursion Insider Quietly Unloads a Major Stake in the Company - TipRanks
리커젼 파마 (RXRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.82%
자본화:
|
볼륨(24시간):